Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2012-02-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
HY12 Financial Results Presentation 16 pages 400.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Results Presentation for six months ended 31 December 2011' and dated 28 February 2012. It contains detailed financial data including revenue, profit, EBITDA, NPAT, EPS, balance sheet figures, cash flow, and segment sales breakdown. The content is structured as a presentation with executive summary, key financials, earnings comparison, balance sheet, cash flow, and product updates. The document length is over 10,000 characters, indicating substantive content rather than a brief announcement. The presence of detailed financial results for a half-year period and the format of a presentation aimed at investors or analysts strongly suggests this is an Interim / Quarterly Report or a Results Presentation. Given the title explicitly states 'Results Presentation' and the detailed financial data is included, the best classification is Interim / Quarterly Report (IR). H1 2012
2012-02-27 English
Final Director`s Interest Notice 2 pages 100.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of a director who has ceased to be a director, including ordinary shares and unlisted options. The content focuses on disclosure of personal share transactions and holdings by a company director. The document length is 2750 characters, which is relatively short and specific to director share interests. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS.
2012-02-16 English
Appendix 3B 7 pages 339.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, specifically employee options in this case. It details the class of securities issued, number of securities, exercise price, vesting dates, and other terms related to the issuance of options. There is no financial performance data, management discussion, or audit information. The document is a formal announcement of a capital raising event (issuance of employee options) and application for quotation of additional securities on the ASX. This fits the category of Capital/Financing Update (CAP).
2012-02-12 English
Initial Director`s Interest Notice 2 pages 92.5KB
Director's Dealing Classification · 95% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options, and states the director's name and appointment date. This is a report of personal share transactions or holdings by a company director. The document length is 2390 characters, which is short and focused solely on director's interests in securities. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). There is no indication that this is an announcement of a report or a certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the correct classification is DIRS with high confidence.
2012-02-12 English
Doryx Generic Update 1 page 75.3KB
Legal Proceedings Report Classification · 95% confidence The document is a company announcement regarding the FDA approval of a generic drug and ongoing patent litigation. It discusses legal proceedings and patent trial dates but does not contain financial data, earnings, or detailed financial reports. It is not a full annual or interim report, nor is it a call transcript or investor presentation. The content focuses on legal and regulatory updates related to product approval and patent litigation, which fits best under Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is LTR with high confidence.
2012-02-09 English
Results of Meeting 1 page 228.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a letter addressed to the ASX Limited regarding the result of an Extraordinary General Meeting (EGM) held on 27 January 2012. It reports the outcome of a shareholder vote on a resolution concerning the issue of options to the Managing Director. The document includes voting results (for, against, abstain, proxy discretion) and is signed by the CFO and Company Secretary. The document length is short (970 characters), and it is clearly an announcement of voting results from a shareholder meeting rather than the meeting materials themselves or a full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2012-01-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.